Heart Failure, Pulmonary Embolism, and Stroke Review

Understanding Heart Failure

  • Heart failure is a complex clinical syndrome where the heart's ability to pump blood is impaired.

Treatment Plans for Heart Failure Patients

  • Diuretics

    • Essential in managing heart failure.

    • Types of diuretics:

    • Loop Diuretics:

      • Example: Furosemide (Lasix).

      • Dosage: 80-100 mg not uncommon during hospital admissions.

      • Purpose: Decrease preload and afterload.

    • Potassium-Sparing Diuretics:

      • Example: Spironolactone.

      • Used for home maintenance to control preload and prevent exacerbations.

    • Loop diuretics are preferred in acute settings due to rapid action.

  • ACE Inhibitors

    • Still prescribed to heart failure patients.

    • Dosage is typically lower; not as powerful and fast-acting as diuretics.

    • Cannot be combined with ARBs (Angiotensin Receptor Blockers) due to the increase risk of hyperkalemia and acute kidney injury.

  • Beta-Blockers

    • Can provide a stronger, effective dose (IV metoprolol recommended).

    • Beta-blockers also help in reducing afterload.

  • Cardiac Glycosides

    • Example: Digoxin.

    • Purpose: A positive inotrope that enhances cardiac contractility (stronger heart contractions).

    • Monitoring: Must check patient's heart rate before administration.

    • Hold if heart rate < 60 bpm and consult healthcare provider.

    • Signs of toxicity include yellow/green vision, nausea, vomiting.

    • Antidote for toxicity: Digibind (Digoxin immune fab).

  • Monitoring Parameters:

    • Electrolyte levels, particularly potassium, when administering diuretics.

    • Vitals for signs of digoxin toxicity and fluid overload.

Mechanisms of Heart Failure

  • Preload: Refers to the volume of blood in the ventricles at the end of diastole (end diastolic volume).

    • Managed by diuretics to reduce fluid overload.

  • Afterload: The resistance the heart must overcome to pump blood.

    • Managed using ACE inhibitors and beta-blockers.

  • Cardiac Output (CO): Amount of blood the heart pumps per minute, affected by preload and afterload.

  • Ejection Fraction (EF): Percentage of blood pumped out of the ventricles with each heartbeat (normal EF = 60-70%).

Types of Heart Failure

  • HFrEF: Heart failure with reduced ejection fraction

    • Often presents with pulmonary congestion issues.

  • HFpEF: Heart failure with preserved ejection fraction

    • More common in elderly patients, associated with a thick, less compliant myocardium.

Diagnostic Tools for Heart Failure

  • Echocardiogram

    • Used to assess heart structure, function, ejection fraction, and reveals wall motion abnormalities.

    • TEE- is used to provide more detailed imaging of the heart, particularly for evaluating heart valves, detecting blood clots in the atria, and assessing endocarditis, by inserting a probe into the esophagus.

    • Chest X-ray: Provides images of the heart's size and shape, can reveal fluid in the lungs, and help identify heart enlargement.

Pulmonary Embolisms

  • A serious condition caused by a blockage in a pulmonary artery, often from DVT thrombosis.

Pathophysiology and Symptoms

  • Main Cause: Deep vein thrombosis (DVT) originating from the legs, which can travel to the lung.

  • RISKS:

  • Immobility

  • Recent Surgery

  • Hormone Therapy (think B/C pills, estrogen replacement therapy) may increase the risk of thromboembolic events.

  • Symptoms may include:

    • Chest pain

    • Shortness of breath (may initially present as cough)

    • Cyanosis or pallor in severe cases.

Diagnostic Approaches

  • CT Pulmonary Angiogram: Gold standard for diagnosing pulmonary embolism.

  • VQ Scan: Ventilation-perfusion scan for assessing blood flow in lungs.

  • Doppler Ultrasound (for suspected DVT cases).

Treatments for Pulmonary Embolisms

  • Anticoagulation Therapy:

    • Initial treatment starts with heparin or LMWH (Low-Molecular Weight Heparin).

  • Thrombolytics:

    • Used to dissolve clots in acute situations.

    • Contraindications include: recent major trauma, uncontrolled hypertension, hemorrhagic stroke.

Stroke Management

  • Types of Stroke:

    • Ischemic Stroke: Caused by a blockage in a blood vessel that supplies blood to the brain, leading to a lack of oxygen and nutrients. This type accounts for about 87% of all strokes.

      • Pathophysiology: Typically occurs when a blood clot (thrombus) forms in an artery supplying the brain (thrombotic stroke) or when a clot formed elsewhere in the body (embolus) travels to the brain (embolic stroke). The lack of blood flow starves brain cells, leading to their death and neurological deficits.

      • Risk Factors: Atherosclerosis (buildup of plaque in arteries), atrial fibrillation (AFib), carotid artery disease, hypertension, diabetes, high cholesterol, smoking, obesity.

      • signs/ symptoms: sensory and motor signs such as weakness or paralysis on one side of the body, difficulty speaking or understanding language, vision problems, and sudden severe headaches. These symptoms often appear abruptly and can vary in severity depending on the region of the brain affected.

    • Hemorrhagic: Caused by a rupture of a blood vessel within the brain, leading to bleeding into the brain tissue or surrounding spaces.

    • Transient Ischemic Attack (TIA): Often called a "mini-stroke," TIA is caused by a temporary disruption of blood flow to the brain, spinal cord, or retina, leading to stroke-like symptoms that last only a few minutes to up to 24 hours and resolve completely without permanent brain damage.

      • Significance: TIA is a warning sign of a future stroke; about 11 in 33 people who have a TIA will eventually have a stroke, with about half occurring within a year after the TIA.

      • Symptoms: Similar to a stroke but temporary, including sudden weakness or numbness on one side of the body, difficulty speaking or understanding speech, vision changes, or dizziness/loss of balance.

      • Management: Requires urgent medical evaluation (often including imaging like CT or MRI, and carotid ultrasound) to identify the cause and initiate preventative measures to reduce the risk of a full stroke (e.g., antiplatelet therapy, blood pressure management, carotid endarterectomy).

Signs and Symptoms of Stroke

  • Facial drooping, unilateral weakness (hemiparesis), confusion, speech difficulties, visual changes.

  • Assessing Risk: The presence of risk factors such as AFib, hypertension, and diabetes increases stroke risks.

Management of Stroke

  • Rapid Assessment:

    • CT scan without contrast to evaluate stroke type; crucial to identify ischemic vs. hemorrhagic to determine appropriate treatment.

  • Thrombolytic Therapy (TPA):

    • Also known as alteplase, this medication dissolves blood clots and can restore blood flow to the brain.

    • Must be administered intravenously within a 3-hour window from symptom onset for eligible ischemic stroke patients.

    • Contraindications: Recent trauma or surgery, active bleeding, uncontrolled hypertension, prior intracranial hemorrhage, severe head trauma.

    • Carotid Endarterectomy:

      • A surgical procedure to remove plaque buildup from the carotid artery in the neck.

      • Purpose: To restore proper blood flow to the brain and reduce the risk of future ischemic strokes or transient ischemic attacks (TIAs) in patients with severe carotid artery stenosis.

      • Risks: this procedure could cause a stroke.

Sickle Cell Disease

  • Genetic disorder characterized by abnormal hemoglobin leading to sickle-shaped red blood cells.

Complications

  • Vaso-occlusive crisis, acute chest syndrome, recurrent pain episodes.

  • Increased risk of infection and blood clots.

Treatment and Management

  • Pain Management:

    • Acute pain (vaso-occlusive crises) is managed with opioids (e.g., morphine, oxycodone) to alleviate severe pain.

    • Hydration therapy with IV fluids is crucial to reduce blood viscosity and prevent further sickling events.

    • Non-pharmacological interventions like warm compresses and rest also play a role.

  • Disease-Modifying Therapy:

    • Hydroxyurea: Decreases sickle cell crisis frequency and severity by increasing the production of fetal hemoglobin (HbF), which prevents sickling of red blood cells.

      • While effective, it carries an increased risk of infection due to its immunosuppressive effects (myelosuppression).

      • Important Lab Monitoring for Hydroxyurea Use:

        • Complete Blood Count (CBC): Essential for monitoring hemoglobin/hematocrit (H/H) levels to assess anemia and red blood cell sickling rates, and white blood cell and platelet counts to detect myelosuppression.

        • Liver Function Tests (LFTs): To assess for potential hepatotoxicity, as hydroxyurea is metabolized in the liver.

        • Kidney Function Tests (KFTs): To monitor renal function (BUN, creatinine), as hydroxyurea is excreted renally, and renal impairment can affect drug clearance.

Overall Nursing Considerations

  • Continuous monitoring of vitals and symptoms in patients with heart failure, pulmonary embolisms, strokes, and sickle cell disease is crucial.

  • Patient education regarding medication adherence, lifestyle changes, and recognition of exacerbation symptoms plays a significant role in managing chronic conditions effectively.